1
|
Rathore SS, Isravel M, Vellaisamy S, Chellappan DR, Cheepurupalli L, Raman T, Ramakrishnan J. Exploration of Antifungal and Immunomodulatory Potentials of a Furanone Derivative to Rescue Disseminated Cryptococosis in Mice. Sci Rep 2017; 7:15400. [PMID: 29133871 PMCID: PMC5684196 DOI: 10.1038/s41598-017-15500-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 10/26/2017] [Indexed: 11/21/2022] Open
Abstract
Cryptococcus neoformans infection is quite complex with both host-pathogen interaction and host immune profile determining disease progress and therapeutic outcome. Hence in the present study, the potential utility of (E)-5-benzylidenedihydrofuran-2(3 H)-one (compound-6) was explored as an effective anticryptococcal compound with immunomodulatory potential. The efficacy of compound-6 in pulmonary cryptococosis model using H99 strain was investigated. The effective dose was found to provide 100% survival, with a significant reduction of yeast burden in lungs and brain. The biodistribution analysis provided evidence for the presence of higher concentration of compound-6 in major organs including lungs and brain. In addition, compound-6 treated mice had significantly higher expression of IL-6, IL-4 and IFN-γ in lung and brain. Similarly, elevated expression of TNF-α, IL-β1 and IL-12 were observed in lungs, suggesting the protective host response against C. neoformans. The reduction and clearance of fungal load in systemic organs and mouse survival are notable results to confirm the ability of compound-6 to treat cryptococcosis. In conclusion, the low molecular weight (174 Da), lipophilicity, its ability to cross blood brain barrier, and facilitating modulation of cytokine expression are the added advantages of compound-6 to combat against disseminated cryptococosis.
Collapse
Affiliation(s)
- Sudarshan Singh Rathore
- Actinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India
| | - Muthukrishnan Isravel
- Department of Chemistry, School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India
| | - Sridharan Vellaisamy
- Department of Chemistry, School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India.,Department of Chemistry and Chemical Sciences, Central University of Jammu, Rahya-Suchani (Bagla), Samba Jammu, J&K, 181143, India
| | - David Raj Chellappan
- Central Animal Facility (CAF), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India
| | - Lalitha Cheepurupalli
- Actinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India
| | - Thiagarajan Raman
- Department of Advanced Zoology and Biotechnology, Ramakrishna Mission Vivekananda College, Mylapore, Chennai, 600004, India
| | - Jayapradha Ramakrishnan
- Actinomycetes Bioprospecting Lab, Centre for Research in Infectious Diseases (CRID), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, Tamilnadu, 613401, India.
| |
Collapse
|
2
|
Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013; 12:323-32. [PMID: 23496671 DOI: 10.1586/erv.13.1] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.
Collapse
Affiliation(s)
- Stephen Brimijoin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
| | | | | | | |
Collapse
|
3
|
Gehlbach PL, Chuck RS, Park CG, Park CY. Viral Transgene Expression Delivered by Repeat Intraocular Adenoviral Vector Injection: in Vivo Live Imaging Study. Mol Imaging 2012. [DOI: 10.2310/7290.2011.00053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Peter L. Gehlbach
- From the Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Ophthalmology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Cancer Research Institute, Tumor Immunity Medical Research Center, Seoul National University, College of Medicine, Seoul, South Korea; and Department of Ophthalmology, Dongguk University Ilsan Hospital, Koyang, South Korea
| | - Roy S. Chuck
- From the Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Ophthalmology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Cancer Research Institute, Tumor Immunity Medical Research Center, Seoul National University, College of Medicine, Seoul, South Korea; and Department of Ophthalmology, Dongguk University Ilsan Hospital, Koyang, South Korea
| | - Chung-Gyu Park
- From the Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Ophthalmology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Cancer Research Institute, Tumor Immunity Medical Research Center, Seoul National University, College of Medicine, Seoul, South Korea; and Department of Ophthalmology, Dongguk University Ilsan Hospital, Koyang, South Korea
| | - Choul Yong Park
- From the Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD; Department of Ophthalmology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Cancer Research Institute, Tumor Immunity Medical Research Center, Seoul National University, College of Medicine, Seoul, South Korea; and Department of Ophthalmology, Dongguk University Ilsan Hospital, Koyang, South Korea
| |
Collapse
|
4
|
Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009; 17:685-96. [PMID: 19174760 DOI: 10.1038/mt.2008.297] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
More than 300 human clinical trials utilize recombinant adenoviruses (rAds) as a gene transfer vector, confirming that rAds continue to be of high clinical interest. A primary weakness of rAds is their known propensity to trigger an innate, proinflammatory immune response rapidly after high-dose, systemic administration. In this study, we investigated what affects that pre-emptive treatment with anti-inflammatory glucocorticoids might have upon Ad vector-triggered inflammatory immune responses. We found that a simple pretreatment regimen with Dexamethasone (DEX) can significantly reduce most Ad-induced innate immune responses. DEX prevented rAd induction of systemic cytokine/chemokine releases in a dose-dependent fashion, with higher dosages preventing rAd induction of acute thrombocytopenia, endothelial cell activation, proinflammatory gene induction, and leukocyte infiltration into transduced organs. Transient glucocorticoid pretreatment also significantly reduced rAd-induced adaptive immune responses, including a decreased induction of Ad-neutralizing antibodies (NAbs). Importantly, use of DEX did not reduce the efficacy of rAd-mediated gene transduction nor rAd-derived transgene expression. Our results demonstrate that a simple, pre-emptive and transient glucocorticoid pretreatment is a viable approach to reduce rAd-associated acute toxicities that currently limit the use of Ad vectors in systemic clinical applications.
Collapse
|
5
|
Chen J, Su C, Lu Q, Shi W, Zhang Q, Wang X, Long J, Yang Q, Li L, Jia X, Wang J, Da W, Liu X, Wu M, Qian Q. Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey. Mol Cancer Ther 2008; 7:1562-8. [PMID: 18524844 DOI: 10.1158/1535-7163.mct-08-0297] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jie Chen
- Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgical Hospital, The Second Military Medical University, Shanghai, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|